Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology
29 mai 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in Upcoming Health Care Investor Conferences
09 mai 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2019 Financial Results
02 mai 2019 16h05 HE
|
Fluidigm Corporation
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First...
Fluidigm Announces 8th Annual Mass Cytometry Summit
30 avr. 2019 09h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results
04 avr. 2019 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
28 mars 2019 08h45 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry
28 mars 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in Upcoming Investor Conferences
22 févr. 2019 17h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results
07 févr. 2019 16h05 HE
|
Fluidigm Corporation
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 millionIncluding...
Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
31 janv. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of a...